Coming up on June 10th, 2014, Orexigen Therapeutics expects a Food and Drug Administration (FDA) for it’s weight loss drug NB32 (Contrave). Contrave was initially rejected by the FDA due to a single issue cardiovascular safety concern and requested the…
$SPY review, $IBB review and select other names. I consider this a bulltrap day as the volume was very low. Refer to January 14th chart for the $SPY. Ukraine issue is definitely much more serious than the market action would…
Seeking Alpha preview: Written by Michael Kovar and Scott Matusow in stock price for Cytokinetics (CYTK) prior to the recent data released last Friday. Indeed, that did occur as the stock went from $10.63 to a high of $13.26, representing…
On Friday of last week, Pozen Inc.(POZN), received a CRL from the FDA, disallowing the New Drug Application (NDA) for its coordinated-delivery tablet combination of omeprazole (Prilosec) and aspirin. This combination can basically be purchased over the counter (OTC) by…
Although we generally look for long plays in the biotechnology sector, certain macroeconomic factors can force us and other investors to look for short ideas. Currently, it’s growing more apparent that money has been shifting, moving out of the pharmaceutical…
Many might not be familiar with who Randal J. Kirk is, but he is an influential man in the small cap biotech investment world. He got his start in business in the early 1980’s and is now Chairman and Chief…
Similar to how a blue-chip company might have an increase in stock price before an earnings call, small-cap developmental biotechs often increase in price before important clinical data releases, Advisory Committee Meetings (ADCOM), and U.S. Food and Drug Administration (FDA)…
Written by Michael Kovar who has a position in $CYTK. Comments: Stock has gapped up a ton this morning, Scott and Kyle have no position, and never had a position in CYTK. Today, we are going to focus on a…
Written by Kyle Dennis and Scott Matusow Today we are going to take a look at a developmental biotech which well-known biotech institutional investor firm Baker Brothers LLC has a substantial position in. The company is developing a blood test…
StockMatusow, stockmatusow (149 clicks) Long/short equity, deep value, value, research analyst Send Message| Follow (3,294) Written by Scott Matusow and Kyle Dennis We typically cover developmental pharmaceutical companies, but this week we want to bring attention to a medical device…
